Kritische 8-K Meldungen
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (19.03.2026)
HOCH Abgang Schlüsselpersonen (19.03.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 19.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | tituted a quorum for the transaction of business. Item 5.02 Departure of Directors or Certain Officers; Election of Dire |
| 09.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | connection with the Name Change or Symbol Change. Item 5.02 Departure of Directors or Certain Officers; Election of Dire |
| 07.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Act). ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain |
| 17.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | bit 99.1 and incorporated herein by reference. Item 5.02 Departure of Directors or Certain Officers; Election of Directo |
| 22.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | release is furnished herewith as Exhibit 99.1. Item 5.02 Departure of Directors or Certain Officers; Election of Directo |
| 08.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | et forth by specific reference in such filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directo |
Stammdaten
LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Unternehmen & Branche
| Name | LeonaBio, Inc. |
|---|---|
| Ticker | LONA |
| CIK | 0001620463 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 34,7 Mio. USD |
| Beta | 2,23 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -105,609,000 | -24.70 | 92,151,000 | 27,790,000 | |
| 2025-09-30 | 10-Q | -6,611,000 | -1.68 | 30,033,000 | 26,786,000 | |
| 2025-06-30 | 10-Q | -6,966,000 | -0.18 | 35,545,000 | 31,986,000 | |
| 2025-03-31 | 10-Q | -9,143,000 | -0.23 | 43,513,000 | 37,330,000 | |
| 2024-12-31 | 10-K | -96,940,000 | -25.19 | 58,779,000 | 44,841,000 | |
| 2024-09-30 | 10-Q | -28,741,000 | -7.46 | 86,246,000 | 57,583,000 | |
| 2024-06-30 | 10-Q | -26,859,000 | -0.70 | 111,253,000 | 83,335,000 | |
| 2024-03-31 | 10-Q | -26,337,000 | -0.69 | 133,458,000 | 106,742,000 | |
| 2023-12-31 | 10-K | -117,672,000 | -3.09 | 160,245,000 | 130,188,000 | |
| 2023-09-30 | 10-Q | -32,970,000 | -0.87 | 184,700,000 | 154,764,000 | |
| 2023-06-30 | 10-Q | -29,597,000 | -0.78 | 208,048,000 | 184,979,000 | |
| 2023-03-31 | 10-Q | -27,820,000 | -0.73 | 232,772,000 | 211,125,000 | |
| 2022-12-31 | 10-K | -95,639,000 | -2.53 | 258,153,000 | 235,137,000 | |
| 2022-09-30 | 10-Q | -20,189,000 | -0.53 | 274,185,000 | 262,249,000 | |
| 2022-06-30 | 10-Q | -24,335,000 | -0.65 | 292,011,000 | 280,565,000 | |
| 2022-03-31 | 10-Q | -20,980,000 | -0.56 | 313,002,000 | 301,977,000 | |
| 2021-12-31 | 10-K | -54,853,000 | -1.49 | 332,008,000 | 321,084,000 | |
| 2021-09-30 | 10-Q | -15,674,000 | -0.42 | 347,331,000 | 336,237,000 | |
| 2021-06-30 | 10-Q | -13,974,000 | 360,124,000 | 350,709,000 | ||
| 2021-03-31 | 10-Q | -8,866,000 | 369,414,000 | 363,217,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | San Martin Javier | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1,720 | 5.37 | -9,236.40 | -119,6% | |
| 2026-03-04 | CHURCH KEVIN | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -1,359 | 5.37 | -7,297.83 | -94,5% | |
| 2026-03-04 | Litton Mark James | Director, Officer, PRESIDENT and CEO | Open Market Sale | -5,156 | 5.37 | -27,687.72 | -358,6% | |
| 2026-03-04 | Renninger Robert | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -906 | 5.37 | -4,865.22 | -63,0% | |
| 2026-03-04 | Worthington Mark | Officer, GENERAL COUNSEL and CCO | Open Market Sale | -1,328 | 5.37 | -7,131.36 | -92,4% | |
| 2026-01-02 | Worthington Mark | Officer, General Counsel and CCO | Open Market Sale | -876 | 6.88 | -6,026.88 | -78,0% | |
| 2026-01-02 | CHURCH KEVIN | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -876 | 6.88 | -6,026.88 | -78,0% | |
| 2026-01-02 | Litton Mark James | Director, Officer, President and CEO | Open Market Sale | -2,586 | 6.88 | -17,791.68 | -230,4% | |
| 2026-01-02 | Renninger Robert | Officer, Chief Financial Officer | Open Market Sale | -297 | 6.88 | -2,043.36 | -26,5% | |
| 2026-01-02 | San Martin Javier | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1,644 | 6.88 | -11,310.72 | -146,5% | |
| 2025-07-01 | San Martin Javier | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -10,842 | 0.29 | -3,182.13 | -41,2% | |
| 2025-07-01 | Renninger Robert | Officer, SVP, Finance and Accounting | Open Market Sale | -2,897 | 0.29 | -850.27 | -11,0% | |
| 2025-07-01 | Worthington Mark | Officer, General Counsel and CCO | Open Market Sale | -8,526 | 0.29 | -2,502.38 | -32,4% | |
| 2025-07-01 | Litton Mark James | Director, Officer, President and CEO | Open Market Sale | -25,123 | 0.29 | -7,373.60 | -95,5% | |
| 2025-07-01 | CHURCH KEVIN | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -8,526 | 0.29 | -2,502.38 | -32,4% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.